What is HC Wainwright’s Forecast for Nuvalent Q2 Earnings?

Nuvalent, Inc. (NASDAQ:NUVL) – HC Wainwright decreased their Q2 2026 earnings estimates for Nuvalent in a research note issued to investors on Monday, May 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($1.46) per share for the quarter, down from their previous forecast of ($1.21). HC Wainwright has a “Buy” rating and a $155.00 price target on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($5.82) per share. HC Wainwright also issued estimates for Nuvalent’s Q3 2026 earnings at ($1.41) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($5.43) EPS, Q2 2027 earnings at ($0.85) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.31) EPS, FY2027 earnings at ($2.84) EPS, FY2028 earnings at $1.60 EPS and FY2029 earnings at $5.83 EPS.

Several other research firms have also recently weighed in on NUVL. Wedbush reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Nuvalent in a research report on Wednesday, April 8th. Cantor Fitzgerald raised their price target on Nuvalent from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a research report on Tuesday, April 21st. Finally, Wells Fargo & Company started coverage on shares of Nuvalent in a research note on Monday, March 30th. They issued an “overweight” rating and a $116.00 target price for the company. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Nuvalent has an average rating of “Moderate Buy” and a consensus target price of $137.25.

Nuvalent Stock Performance

Shares of NASDAQ:NUVL opened at $102.54 on Wednesday. The company has a 50 day moving average price of $101.98 and a two-hundred day moving average price of $102.53. Nuvalent has a 52 week low of $68.64 and a 52 week high of $113.01. The company has a market capitalization of $8.06 billion, a PE ratio of -16.92 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last issued its earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the prior year, the company posted ($1.18) EPS.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, insider Deborah Ann Miller sold 5,500 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $99.22, for a total transaction of $545,710.00. Following the transaction, the insider owned 59,634 shares in the company, valued at $5,916,885.48. This trade represents a 8.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James Richard Porter sold 30,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $101.69, for a total value of $3,050,700.00. Following the sale, the chief executive officer owned 324,879 shares of the company’s stock, valued at approximately $33,036,945.51. The trade was a 8.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 80,023 shares of company stock valued at $8,235,217 over the last ninety days. Company insiders own 5.02% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in NUVL. Candriam S.C.A. boosted its holdings in shares of Nuvalent by 9.4% in the 3rd quarter. Candriam S.C.A. now owns 329,721 shares of the company’s stock valued at $28,514,000 after purchasing an additional 28,462 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Nuvalent during the 3rd quarter worth $1,297,000. SG Americas Securities LLC acquired a new stake in Nuvalent in the third quarter valued at about $1,629,000. Aberdeen Group plc boosted its stake in Nuvalent by 115.4% in the fourth quarter. Aberdeen Group plc now owns 165,177 shares of the company’s stock valued at $16,615,000 after buying an additional 88,489 shares in the last quarter. Finally, HighVista Strategies LLC grew its position in Nuvalent by 84.9% in the third quarter. HighVista Strategies LLC now owns 93,294 shares of the company’s stock valued at $8,068,000 after acquiring an additional 42,834 shares during the last quarter. 97.26% of the stock is owned by institutional investors.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.